Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued
Reference number: GID-TA10711
Following on from information provided to NICE by the company in September 2021, the appraisal of Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.